Business
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-endCash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13
About this update from Ovid Therapeutics Inc.
[{"type":"image","alt":"Ovid Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ovid Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/27DLXferaeZxhRE9vCTuYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end","length":168,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026","length":189,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":488,"olType":false},{"type":"text","content":"NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the first quarter ended March 31, 2025.","length":311,"tagName":"p"},{"type":"text","content":"“We’re off to a strong start across our pipeline and programs in what will be a defining year for Ovid,” said Dr. Jeremy Levin, D.Phil., MB BChir., Chairman and CEO of Ovid Therapeutics. “Our lead program, OV329, continues to show promise as a potential next-generation medicine for treatment resistant seizures, and we are on track to share key safety and biomarker data later this year. We’ve also initiated human trials of our first-in-class KCC2 direct activator—a long-sought biological target in central nervous system drug development because it is considered to be a “master switch” on neural hyperexcitability. We are excited for these readouts and anticipate that OV4071, our first ...